Obesity Hormones in Health and Disease


Obesity is a medical condition as excess body weight in the form of fat, resulting from a chronic imbalance of energy homoeostasis. The prevalence of obesity in adults and children is rapidly rising and it is now the major contributors to metabolic disorders. Energy balance is controlled with short‐ and long‐term signals generated by the central nervous system, gastrointestinal tract and adipose tissue. The knowledge of obesity hormones (adipokines) released by adipose tissue will allow us to develop new anti‐obesity pharmacotherapies amplifying anorexigenic and lipolytic signalling or blocking orexigenic and lipogenic signalling.

Key Concepts:

  • Obesity is a medical condition resulting from the failure of energy homoeostasis. Obesity is most prevalent in westernised countries, associated with some chronic diseases (i.e. type 2 diabetes, cardiovascular diseases and cancers), shortens life duration and the increases mortality rates.

  • There has been important endocrine alterations in many physiological systems are attracting interest to understand the pathological mechanisms of obesity.

  • Although adipose tissue can be considered as storage organ of excess energy, adipocytes released adipokines to control the growth of adipose tissue or the energy homoeostasis and body weight regulation.

  • Obesity hormones (adipokines) released by adipose tissue to play a major role in the regulation of energy homoeostasis such as adiponectin, apelin, angiotensin II, ASP, leptin, PAI‐1, MCP‐1, omentin, resistin, visfatin, proinflammmatory cytokines and glucocorticoids.

  • Understanding the physiological and pathological roles of adipokines in health and disease in humans will allow us to find potential therapeutic targets for the treatment of obesity‐related disorders.

Keywords: obesity; adiponectin; apelin; angiotensin II; ASP; leptin; PAI‐1; MCP‐1; omentin; resistin; visfatin; glucocorticoids; type 2 diabetes

Figure 1.

In human body, the (ARC) is the major target for short‐term signals that regulate human appetite. ARC contains two distinct neuronal subtypes expressing the anorexigenic (appetite decreasing) neuropeptides, POMC, and CART or expressing orexigenic (appetite stimulating) neuropeptides, NPY and AgRP (Hagan and Niswender, ; Parker and Bloom, ). Long‐term signals are generated for metabolic energy needs of body, regulated by hormonal systems as leptin and insulin (Harrold, ). Leptin is predominantly synthesised by WAT, reduces food intake and increases energy expenditure, resulting in body weight loss. Insulin is secreted by pancreatic β‐cells in response to elevated blood glucose. Thus, glucose is metabolised and excess energy stored as glycogen (Pliquett et al., ). Leptin and insulin inhibit anabolic neural circuits and stimulate catabolic circuits to increase energy expenditure.



Adeghate E (2008) Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Current Medicinal Chemistry 15(18): 1851–1862.

Alvarez‐Castro P, Sangiao‐Alvarellos S, Brandon‐Sanda I and Cordido F (2011) Endocrine function in obesity. Endocrinologia Nutricion (English Edition) 58(8): 422–432.

Burman KD, Ousman YH and Devdhar MR (2009) Endocrine function in obesity. In: Weickert MO (ed.). Obesity. Chapter 12. http://www.endotext.org/obesity/obesity12/obesityframe12.htm

Castan‐Laurell I, Dray C, Attané C et al. (2011) Apelin, diabetes, and obesity. Endocrine 40(1): 1–9.

Deshmane SL, Kremlev S, Amini S and Sawaya BE (2009) Monocyte chemoattractant protein‐1 (MCP‐1): an overview. Journal of Interferon and Cytokine Research 29(6): 313–326.

Eder K, Baffy N, Falus A and Fulop AK (2009) The major inflammatory mediator interleukin‐6 and obesity. Inflammation Research 58(11): 727–736.

Gautron L and Elmquist JK (2011) Sixteen years and counting: an update on leptin in energy balance. Journal of Clinical Investigation 121(6): 2087–2093.

Gnacinska M, Malgorzewicz S, Stojek M, Lysiak‐Szydlowska W and Sworczak K (2009) Role of adipokines in complications related to obesity. Advances in Medical Sciences 54(2): 150–157.

Hagan S and Niswender KD (2012) Neuroendocrine regulation of food intake. Pediatric Blood Cancer 58(1): 149–153.

Harrold JA (2004) Hypothalamic control of energy balance. Current Drug Targets 5(3): 207–219.

Houseknecht KL and Spurlock ME (2003) Leptin regulation of lipid homeostasis: dietary and metabolic implications. Nutrition Research Reviews 16(1): 83–96.

IASO/IOTF (2010) Obesity the global epidemic. http://www.iaso.org/iotf/obesity/obesitytheglobalepidemic/

Kershaw EE, Morton NM, Dhillon H et al. (2005) Adipocyte‐specific glucocorticoid inactivation protects against diet‐induced obesity. Diabetes 54(4): 1023–1031.

Li M‐D (2011) Leptin and beyond: an odyssey to the central control of body weight. Yale Journal of Biology and Medicine 84(1): 1–7.

Li S, Shin HJ, Ding EL and van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta‐analysis. Journal of the American Medical Association 302(2): 179–188.

Maenhaut N and Voorde JV (2011) Regulation of vascular tone by adipocytes. BMC Medicine 9(25): 1–12.

Mangge H, Almer G, Truschnig‐Wilders M et al. (2010) Inflammation, adiponectin, obesity and cardiovascular risk. Current Medicinal Chemistry 17(36): 4511–4520.

Massiera F, Bloch‐Faure M, Ceiler D et al. (2001) Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB Journal 15(14): 2727–2729.

Murray I, Kohl J and Cianflone K (1999) Acylation‐stimulating protein (ASP): structure‐function determinants of cell surface binding and triacylglycerol synthetic activity. Biochemical Journal 342(1): 41–48.

O'Rourke RW (2009) Inflammation in obesity‐related disease. Surgery 145: 255–259.

Park HS, Park JY and Yu R (2005) Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF‐alpha and IL‐6. Diabetes Research and Clinical Practice 69(1): 29–35.

Parker JA and Bloom SR (2012) Hypothalamic neuropeptides and the regulation of appetite. Neuropharmacology 63(1): 18–30 [Epub ahead of print].

Pliquett RU, Fuhrer D, Falk S et al. (2006) The effects of insulin on the central nervous system – focus on appetite regulation. Hormone and Metabolic Research 38(7): 442–446.

Saleh J, Al‐Wardy N, Farhan H, Al‐Khanbashi M and Cianflone K (2011) Acylation stimulating protein: a female lipogenic factor? Obesity Reviews 12(6): 440–448.

Vazquez‐Vela ME, Torres N and Tovar AR (2008) White adipose tissue as endocrine organ and its role in obesity. Archives Medicine Research 39(8): 715–728.

Zaninotto P, Head J, Stamatakis E, Wardle H and Mindell J (2009) Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. Journal of Epidemiology and Community Health 63(2): 140–146.

Further Reading

Aydin S, Ozkan Y, Caylak E and Aydin S (2006) Ghrelin and its biochemical functions: Review. Journal of Medical Sciences 26(3): 272–283.

Boguszewski CL, Paz‐Filho G and Velloso LA (2010) Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain. Endokrynologia Polska 61(2): 194–206.

Cummings DE and Overduin J (2007) Gastrointestinal regulation of food intake. Journal of Clinical Investigation 117(1): 13–23.

Neary MT and Batterham RL (2009) Gut hormones: implications for the treatment of obesity. Pharmacology and Therapeutics 124(1): 44–56.

Suzuki K, Simpson KA, Minnion JS, Shillito JC and Bloom SR (2010) The role of gut hormones and the hypothalamus in appetite regulation. Endocrine Journal 57(5): 359–372.

Wilding JP (2002) Neuropeptides and appetite control. Diabetic Medicine 19(8): 619–627.

Williams G and Frühbeck G (eds), (2009) Obesity: Science to Practice. Oxford: John Wiley & Sons, Ltd.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Caylak, Emrah(Aug 2012) Obesity Hormones in Health and Disease. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0024166]